REG - Competition and Mkts - Merger Update: Theramex / Viatris

ViatrisAnnouncement

12/08/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240812:nRSL1214Aa&default-theme=true

RNS Number : 1214A  Competition and Markets Authority  12 August 2024

Acceptance of Undertakings in lieu: Anticipated Acquisition by Theramex HQ UK
Ltd of the European Rights to Viatris' Femoston and Duphaston products

The CMA has today accepted undertakings in lieu of reference to an in-depth,
Phase 2 investigation given by Theramex HQ UK Ltd and Viatris, Inc under
section 73 of the Enterprise Act 2002. The anticipated acquisition by Theramex
of the European Rights to Viatris' Femoston and Duphaston products will
therefore not be referred to an in-depth, Phase 2 investigation and the
undertakings which have been signed by Theramex HQ UK Ltd and Viatris, Inc
will come into effect from this date.

The text of this decision will be placed on the dedicated case page on the
Competition and Markets Authority's website at
https://www.gov.uk/cma-cases/theramex-slash-european-rights-to-viatris-femoston-and-duphaston-products
(https://www.gov.uk/cma-cases/theramex-slash-european-rights-to-viatris-femoston-and-duphaston-products)
as soon as is reasonably practical.

In the event of media enquiries please email press@cma.gov.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MERFLFSLTTIFLIS